Comment · Tue, March 19, 2013
MDMA-Assisted Therapy for Social Anxiety in Autistic Adults: Protocol Submitted to FDA
Original post in this thread
MAPSPsychedelic · 13 points
On February 28, 2013, the protocol ( full protocol ) | synopsis ) for our planned study of MDMA-assisted therapy for social anxiety in autistic adults was submitted to the U.S. Food and Drug Administration for review. This will be a MAPS-sponsored collaborative study between Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the Stanford University School of Medicine. Social anxiety is prevalent in autistic adults, and often compounds the considerable social challenges faced by autistic adults. The main objective of this study is to collect data on the safety of MDMA-assisted therapy in autistic adults, and to use standard clinical measures to estimate the extent to which MDMA-assisted therapy may reduce social anxiety symptoms in this group. Even though we did attempt to obtain external funding from a private foundation, our letter of intent was rejected. Please consider donating to help complete this study.
Alicia Danforth, Ph.D.(c), will present the results of her research on the [MD…
What they were answering
FuzzyBacon · 1 points
Is it possible the 225mg dosage is cumulative? My understanding of mdma-ptsd therapy was 2-3 sessions, and 3x 75mg would be consistent with most studies for dosage.
u/MisterYouAreSoDumb
It's possible. If it is, their wording is confusing. The MAPS study is going to use 50mg, 100mg, and 125mg, with a possible re-dose. They were comparing the 225mg of other studies directly to their 125mg dose. That's why I associated it with a single dose.